.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Merck
US Department of Justice
Accenture
McKinsey
Johnson and Johnson
Chubb
Fish and Richardson
Deloitte

Generated: September 25, 2017

DrugPatentWatch Database Preview

SPRYCEL Drug Profile

« Back to Dashboard

What is the patent landscape for Sprycel, and when can generic versions of Sprycel launch?

Sprycel is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are five patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and ten patent family members in thirty-nine countries.

The generic ingredient in SPRYCEL is dasatinib. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dasatinib profile page.

Summary for Tradename: SPRYCEL

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list94
Clinical Trials: see list46
Patent Applications: see list3,878
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SPRYCEL at DailyMed

Pharmacology for Tradename: SPRYCEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-006Oct 28, 2010RXYesNo► Subscribe► SubscribeYY ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-004May 30, 2008ABRXYesYes► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-004May 30, 2008ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-001Jun 28, 2006ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-003Jun 28, 2006ABRXYesNo► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-005Oct 28, 2010RXYesNo► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-006Oct 28, 2010RXYesNo► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-006Oct 28, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-001Jun 28, 2006ABRXYesNo► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-003Jun 28, 2006ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for SPRYCEL

Drugname Dosage Strength RLD Submissiondate
dasatinibTablets80 mg and 140 mgSprycel6/17/2011
dasatinibTablets80 mg and 140 mgSprycel6/16/2011
dasatinibTablets20 mg, 50 mg, 70 mg and 100 mgSprycel6/28/2010

Non-Orange Book Patents for Tradename: SPRYCEL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,979,694 Cyclic protein tyrosine kinase inhibitors► Subscribe
8,716,323Cyclic protein tyrosine kinase inhibitors► Subscribe
8,242,270Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors► Subscribe
7,189,854Cyclic protein tyrosine kinase inhibitors► Subscribe
8,993,567Cyclic protein tyrosine kinase inhibitors► Subscribe
7,091,223Cyclic protein tyrosine kinase inhibitors► Subscribe
9,382,219Cyclic protein tyrosine kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SPRYCEL

Country Document Number Estimated Expiration
Norway322470► Subscribe
Russian Federation2365372► Subscribe
Slovenia1711481► Subscribe
Serbia52291► Subscribe
Israel177280► Subscribe
BrazilPI0515721► Subscribe
Canada2555291► Subscribe
BrazilPI0507476► Subscribe
Denmark1610780► Subscribe
Denmark1711481► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SPRYCEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13/003Ireland► SubscribePRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120
2013 00006Denmark► Subscribe
0567Netherlands► SubscribePRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 - 009 20061120
00567Netherlands► SubscribePRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 .... 009 20061120
90004-8Sweden► SubscribePRODUCT NAME: DASATINIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/06/363/001 20061120
146Luxembourg► SubscribePRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
C0003France► SubscribePRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/06/363/001 20061122
2013000012Germany► SubscribePRODUCT NAME: DASATINIB UND PHARMAZEUTISCH GEEIGNETE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-009 EU/1/06/363/010-011 EU/1/06/363/012-015 20061120
1169038/01Switzerland► SubscribeFORMER OWNER: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Queensland Health
Chinese Patent Office
Federal Trade Commission
Moodys
Harvard Business School
Boehringer Ingelheim
Fish and Richardson
Covington
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot